Samrat Pharmachem Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Lalit Mehta

Chief executive officer

₹4.8m

Total compensation

CEO salary percentage	100.0%
CEO tenure	32.4yrs
CEO ownership	14.0%
Management average tenure	no data
Board average tenure	9.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Lalit Mehta's remuneration changed compared to Samrat Pharmachem's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	₹65m
Jun 30 2024	n/a	n/a	₹36m
Mar 31 2024	₹5m	₹5m	₹22m
Dec 31 2023	n/a	n/a	₹225k
Sep 30 2023	n/a	n/a	₹18m
Jun 30 2023	n/a	n/a	₹79m
Mar 31 2023	₹4m	₹4m	₹166m
Dec 31 2022	n/a	n/a	₹244m
Sep 30 2022	n/a	n/a	₹287m
Jun 30 2022	n/a	n/a	₹256m
Mar 31 2022	₹4m	₹4m	₹172m
Dec 31 2021	n/a	n/a	₹117m
Sep 30 2021	n/a	n/a	₹68m
Jun 30 2021	n/a	n/a	₹55m
Mar 31 2021	₹2m	₹2m	₹53m
Dec 31 2020	n/a	n/a	₹42m
Sep 30 2020	n/a	n/a	₹31m
Jun 30 2020	n/a	n/a	₹32m
Mar 31 2020	₹2m	₹2m	₹42m
Dec 31 2019	n/a	n/a	₹51m
Sep 30 2019	n/a	n/a	₹50m
Jun 30 2019	n/a	n/a	₹34m
Mar 31 2019	₹2m	₹2m	₹15m
Dec 31 2018	n/a	n/a	₹9m
Sep 30 2018	n/a	n/a	₹21m
Jun 30 2018	n/a	n/a	₹27m
Mar 31 2018	₹2m	₹2m	₹32m

Compensation vs Market: Lalit's total compensation ($USD56.84K) is above average for companies of similar size in the Indian market ($USD42.63K).

Compensation vs Earnings: Lalit's compensation has increased by more than 20% in the past year.

CEO

Lalit Mehta (88 yo)

32.4yrs

Tenure

₹4,800,000

Compensation

Mr. Lalit Damodar Mehta serves as the Chairman, Chief Executive Officer and Managing Director at Samrat Pharmachem Limited and has been its Non-Independent Executive Director since June 16, 1992. Mr. Mehta...

Board Members

Name	Position	Tenure	Compensation	Ownership
Lalit Mehta	Founder	32.4yrs	₹4.80m	13.97% ₹ 190.3m
Rajesh Mehta	CFO & Non-Independent Executive Director	32.4yrs	₹4.20m	12.41% ₹ 169.1m
Megh Mehta	Non-Independent Executive Director	9.1yrs	₹2.10m	1.71% ₹ 23.3m
Renu Dharod	Non-Executive Independent Director	9.8yrs	₹200.00k	0.00081% ₹ 11.0k
Manishkumar Pipalia	Non-Executive Independent Director	less than a year	no data	no data
Sachin Kothary	Non-Executive Independent Director	less than a year	no data	no data
Megha Jain	Non-Executive Independent Director	less than a year	no data	no data

9.1yrs

Average Tenure

55yo

Average Age

Experienced Board: 530125's board of directors are considered experienced (9.1 years average tenure).

Samrat Pharmachem Management

Management criteria checks 1/4

Key information

Recent management updates

Samrat Pharmachem Limited Announces Director Resignations

Samrat Pharmachem Limited Announces Director Resignations

Samrat Pharmachem Limited, Annual General Meeting, Sep 26, 2024

Samrat Pharmachem Limited, Annual General Meeting, Sep 28, 2023

Insufficient new directors

Samrat Pharmachem Limited, Annual General Meeting, Sep 30, 2022

Recent updates

Second quarter 2025 earnings released: EPS: ₹8.61 (vs ₹0.61 loss in 2Q 2024)

Samrat Pharmachem Limited to Report First Half, 2025 Results on Nov 14, 2024

New minor risk - Share price stability

Now 27% overvalued after recent price rise

Investor sentiment improves as stock rises 17%

Samrat Pharmachem Limited Proposes Dividend for Fiscal Year 2023-24, Payable on or Before October 25, 2024

Investor sentiment improves as stock rises 19%

First quarter 2025 earnings released: EPS: ₹6.68 (vs ₹1.98 in 1Q 2024)

Samrat Pharmachem Limited Announces Director Resignations

Samrat Pharmachem Limited Announces Director Resignations

Samrat Pharmachem Limited to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings released: EPS: ₹7.00 (vs ₹53.83 in FY 2023)

Dividend of ₹1.00 announced

Samrat Pharmachem Limited, Annual General Meeting, Sep 26, 2024

Samrat Pharmachem Limited to Report Q4, 2024 Results on May 30, 2024

Third quarter 2024 earnings released: EPS: ₹1.11 (vs ₹6.78 in 3Q 2023)

Samrat Pharmachem Limited to Report Q3, 2023 Results on Feb 14, 2024

Second quarter 2024 earnings released: ₹0.61 loss per share (vs ₹19.14 profit in 2Q 2023)

Samrat Pharmachem Limited to Report Q2, 2024 Results on Nov 08, 2023

Upcoming dividend of ₹1.00 per share at 0.2% yield

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: ₹1.98 (vs ₹30.32 in 1Q 2023)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 17%

Samrat Pharmachem Limited to Report Q1, 2024 Results on Aug 14, 2023

Full year 2023 earnings released: EPS: ₹53.83 (vs ₹55.62 in FY 2022)

Samrat Pharmachem Limited Recommends Dividend for the Financial Year Ended March 31, 2023

Samrat Pharmachem Limited, Annual General Meeting, Sep 28, 2023

Investor sentiment improves as stock rises 21%

Investor sentiment deteriorates as stock falls 15%

Third quarter 2023 earnings released: EPS: ₹6.78 (vs ₹20.87 in 3Q 2022)

Samrat Pharmachem Limited to Report Q4, 2022 Results on Feb 14, 2023

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Insufficient new directors

Samrat Pharmachem Limited to Report Q2, 2023 Results on Nov 14, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Samrat Pharmachem Limited, Annual General Meeting, Sep 30, 2022

Investor sentiment improved over the past week

Samrat Pharmachem Limited to Report Q1, 2023 Results on Aug 13, 2022

Full year 2022 earnings released: EPS: ₹55.62 (vs ₹17.26 in FY 2021)

Samrat Pharmachem Limited Recommends Dividend for the Financial Year Ended March 31, 2022

Investor sentiment deteriorated over the past week

Insufficient new directors

Samrat Pharmachem Limited to Report Q4, 2022 Results on May 30, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹9.03 (vs ₹4.66 in 2Q 2021)

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS ₹3.09 (vs ₹2.58 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹17.26 (vs ₹13.71 in FY 2020)

Investor sentiment improved over the past week

New 90-day high: ₹152

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ₹4.97 (vs ₹1.52 in 3Q 2020)

Samrat Pharmachem Limited to Report Q3, 2021 Results on Feb 13, 2021

Samrat Pharmachem Limited, Annual General Meeting, Dec 31, 2020

New 90-day high: ₹133

Market bids up stock over the past week

Second quarter 2021 earnings released: EPS ₹4.66

Market bids up stock over the past week

First quarter earnings released

Samrat Pharmachem Limited to Report Q1, 2020 Results on Sep 14, 2020

New 90-day high - ₹103

Samrat Pharmachem Limited to Report Fiscal Year 2020 Results on Jul 31, 2020

CEO Compensation Analysis